Immunome Inc. Reports on Security Holder Vote
Ticker: IMNM · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Immunome Inc. held a shareholder vote on June 12th, details to follow.
AI Summary
Immunome, Inc. filed an 8-K on June 13, 2024, reporting on matters submitted to a vote of its security holders on June 12, 2024. The filing details the company's corporate information, including its incorporation in Delaware and principal executive offices in Bothell, Washington.
Why It Matters
This filing indicates that Immunome, Inc. held a vote of its security holders, which could pertain to significant corporate decisions or changes.
Risk Assessment
Risk Level: low — This is a routine filing reporting on a shareholder vote, not indicating immediate financial distress or significant new risks.
Key Players & Entities
- Immunome, Inc. (company) — Registrant
- June 12, 2024 (date) — Date of earliest event reported
- June 13, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Bothell, Washington (location) — Address of principal executive offices
FAQ
What specific matters were submitted to a vote of Immunome Inc.'s security holders on June 12, 2024?
The filing states that matters were submitted to a vote of security holders on June 12, 2024, but does not specify the exact nature of these matters in the provided text.
When was the Form 8-K filed with the SEC?
The Form 8-K was filed on June 13, 2024.
What is Immunome Inc.'s state of incorporation?
Immunome Inc. is incorporated in Delaware.
Where are Immunome Inc.'s principal executive offices located?
Immunome Inc.'s principal executive offices are located at 18702 N. Creek Parkway, Suite 100, Bothell, Washington, 98011.
What is the company's IRS Employer Identification Number?
Immunome Inc.'s IRS Employer Identification Number is 77-0694340.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-06-13 16:05:42
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
Filing Documents
- tm2417104d1_8k.htm (8-K) — 29KB
- 0001104659-24-071253.txt ( ) — 199KB
- immu-20240612.xsd (EX-101.SCH) — 3KB
- immu-20240612_lab.xml (EX-101.LAB) — 33KB
- immu-20240612_pre.xml (EX-101.PRE) — 22KB
- tm2417104d1_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders Immunome, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders on June 12, 2024 (the "Annual Meeting"). As of April 25, 2024, the record date for the Annual Meeting, 59,943,368 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Proposal 1: Election of Directors The Company's stockholders elected the two persons below as Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Clay B. Siegall, Ph.D. 43,295,914 80,139 6,682,195 Carol A. Schafer 33,452,580 9,923,473 6,682,195 Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 50,008,641 29,664 19,943 —
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMMUNOME, INC. Date: June 13, 2024 By: /s/ Max Rosett Name: Max Rosett Title: Chief Financial Officer